Business Standard

Glenmark Pharma hits four-year high, surges 10% in two days

The company has entered into an agreement with Forest Labs to develop novel mPGES-1 inhibitors to treat chronic inflammatory conditions, including pain.

SI Reporter  |  Mumbai 

Glenmark Pharmaceuticals has rallied over 5% to Rs 547, its highest level since September 2008, with heavy volumes on the NSE. The stock opened at Rs 522 and has seen a combined 1.28 million shares changing hands on the counter so far compared to less than one million shares that were traded daily in past two weeks.

The stock has outperformed the market by surging 10% in past two trading sessions compared to 1% rise in benchmark Sensex after the company informed the stock exchanges that it has entered into an agreement with (Forest Labs) to develop novel mPGES-1 inhibitors to treat chronic inflammatory conditions, including pain.

Under the terms of agreement, Forest Labs will make a $6-million up-front payment and provide an additional $3 million to support the next phase of work. Forest Labs will make other future payments in FY2014 to support the ongoing mPGES-1 inhibitors programme.

Analyst at Sharekhan recommended a BUY on the stock with the revised target price of Rs 600 saying that it an important development for the company having positive repercussions in the long term.

RECOMMENDED FOR YOU

Glenmark Pharma hits four-year high, surges 10% in two days

The company has entered into an agreement with Forest Labs to develop novel mPGES-1 inhibitors to treat chronic inflammatory conditions, including pain.

Glenmark Pharmaceuticals has rallied over 5% to Rs 547, its highest level since September 2008, with heavy volumes on the NSE. The stock opened at Rs 522 and has seen a combined 1.28 million shares changing hands on the counter so far compared to less than one million shares that were traded daily in past two weeks.

Glenmark Pharmaceuticals has rallied over 5% to Rs 547, its highest level since September 2008, with heavy volumes on the NSE. The stock opened at Rs 522 and has seen a combined 1.28 million shares changing hands on the counter so far compared to less than one million shares that were traded daily in past two weeks.

The stock has outperformed the market by surging 10% in past two trading sessions compared to 1% rise in benchmark Sensex after the company informed the stock exchanges that it has entered into an agreement with (Forest Labs) to develop novel mPGES-1 inhibitors to treat chronic inflammatory conditions, including pain.

Under the terms of agreement, Forest Labs will make a $6-million up-front payment and provide an additional $3 million to support the next phase of work. Forest Labs will make other future payments in FY2014 to support the ongoing mPGES-1 inhibitors programme.

Analyst at Sharekhan recommended a BUY on the stock with the revised target price of Rs 600 saying that it an important development for the company having positive repercussions in the long term.

image

LIVE MARKET

BSE

  ( %)

NSE

  ( %)

Widgets Magazine

More News

STOCK WATCH

Company Price() Chg(%)
V-Guard Inds. 1186.90 20.00
Carborundum Uni. 206.00 7.77
Indbull.RealEst. 72.30 6.87
Aarti Drugs 491.00 5.71
KRBL 255.70 5.36
> More on BSE Gainers
Company Price() Chg(%)
V-Guard Inds. 1194.95 20.00
Indbull.RealEst. 72.25 6.80
Aarti Drugs 491.20 5.57
KRBL 256.45 5.32
Tata Tele. Mah. 6.95 5.30
> More on NSE Gainers
Company Price() Chg(%)
Godrej Propert. 316.40 -5.89
Idea Cellular 112.80 -5.69
Castex Tech 7.67 -4.96
Balkrishna Inds 661.55 -4.41
Adani Ports 199.00 -4.17
> More on BSE Gainers
Company Price() Chg(%)
ABG Shipyard 39.50 -7.49
Idea Cellular 112.70 -5.97
Godrej Propert. 316.90 -5.66
Adani Ports 198.70 -4.59
Castex Tech 7.55 -4.43
> More on NSE Gainers
Widgets Magazine
Widgets Magazine
Widgets Magazine

Derivatives

Index
Instrument Type
Expiry Date
Option Type
Strike Price

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard